Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

Phase 2

Terminated

Conditions: Extrahepatic Cholangiocarcinoma
Advanced Biliary Tract Cancer
Gallbladder Carcinoma
Intrahepatic Cholangiocarcinoma

Interventions: Drug: Irinotecan Liposome Injection
Drug: Fluorouracil
Drug: SG001
Drug: Leucovorin

First Posted Date: 2021-08-18

Last Posted Date: 2024-07-11

Lead Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Target Recruit Count: 17

Registration Number: NCT05009953

Locations: 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China

Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo

Phase 4

Conditions: Vitiligo

Interventions: Drug: Methotrexate
Drug: 5-fluorouracil
Device: Fractional CO2 laser

First Posted Date: 2021-08-17

Last Posted Date: 2022-05-09

Lead Sponsor: Assiut University

Target Recruit Count: 50

Registration Number: NCT05008887

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Phase 2

Active, not recruiting

Conditions: Rectal Neoplasms
Rectal Cancer

Interventions: Radiation: Radiotherapy
Drug: Capecitabine
Drug: Fluorouracil
Drug: Atezolizumab
Drug: Tiragolumab

First Posted Date: 2021-08-17

Last Posted Date: 2024-11-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 58

Registration Number: NCT05009069

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou City, China
🇨🇳
Zhongshan Hospital Fudan University, Shanghai, China

and more 2 locations

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

First Posted Date: 2021-08-16

Last Posted Date: 2024-10-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 604

Registration Number: NCT05007106

Locations: 🇺🇸
Memorial Sloan Kettering - Bergen ( Site 1025), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering - Monmouth ( Site 1022), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering - Basking Ridge ( Site 1023), Basking Ridge, New Jersey, United States

and more 70 locations

AB122 Platform Study

First Posted Date: 2021-08-11

Last Posted Date: 2024-02-16

Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Target Recruit Count: 715

Registration Number: NCT04999761

Locations: 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Wakayama, Japan

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

Phase 3

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: PD-1 inhibitor
Drug: Oxaliplatin
Drug: Capecitabine
Drug: Tegafur-gimeracil-oteracil potassium
Drug: 5-FU
Radiation: Radiotherapy
Drug: Chemotherapy

First Posted Date: 2021-08-10

Last Posted Date: 2021-08-10

Lead Sponsor: Fudan University

Target Recruit Count: 433

Registration Number: NCT04997837

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Phase 3

Recruiting

Conditions: Metastatic Esophageal Squamous Cell Carcinoma

Interventions: Biological: Pembrolizumab
Drug: Lenvatinib
Drug: 5-FU
Drug: Oxaliplatin
Drug: Cisplatin
Drug: Paclitaxel
Drug: Leucovorin
Drug: Levoleucovorin

First Posted Date: 2021-07-02

Last Posted Date: 2024-12-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 862

Registration Number: NCT04949256

Locations: 🇨🇷
PROCLINICAL Pharma ( Site 0904), San José, San Jose, Costa Rica
🇨🇳
Shanxi Provincial Cancer Hospital ( Site 8019), Taiyuan, Shanxi, China
🇨🇳
West China Hospital of Sichuan University ( Site 8048), Chengdu, Sichuan, China

and more 192 locations

Perioperative Chemotherapy in Gastric Cancer

Phase 2

Terminated

Conditions: Gastric Cancer

Interventions: Drug: Capecitabine
Drug: Docetaxel
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Fluorouracil

First Posted Date: 2021-06-24

Last Posted Date: 2024-11-06

Lead Sponsor: Ukrainian Society of Clinical Oncology

Target Recruit Count: 69

Registration Number: NCT04937738

Locations: 🇺🇦
National Cancer Institute, Kyiv, Ukraine

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Phase 2

Recruiting

Conditions: AIDS-Related Anal Carcinoma
Anal Margin Squamous Cell Carcinoma
Anal Non-Keratinizing Squamous Cell Carcinoma
Anal Squamous Cell Carcinoma
HIV Infection
Rectal Squamous Cell Carcinoma
Stage II Rectal Cancer AJCC v8
Stage IIB Anal Cancer AJCC v8
Stage III Anal Cancer AJCC v8
Stage III Rectal Cancer AJCC v8

Interventions: Procedure: Anoscopy
Procedure: Biospecimen Collection
Procedure: Colonoscopy
Drug: Capecitabine
Procedure: Computed Tomography
Procedure: Digital Rectal Examination
Procedure: Echocardiography
Biological: Nivolumab
Procedure: Proctoscopy
Other: Fludeoxyglucose F-18
Other: Questionnaire Administration
Drug: Fluorouracil
Procedure: Sigmoidoscopy
Radiation: Intensity-Modulated Radiation Therapy
Procedure: Lymph Node Biopsy
Procedure: Magnetic Resonance Imaging
Drug: Mitomycin
Procedure: Positron Emission Tomography

First Posted Date: 2021-06-18

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT04929028

Locations: 🇺🇸
Zuckerberg San Francisco General Hospital, San Francisco, California, United States
🇺🇸
George Washington University Medical Center, Washington, District of Columbia, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 10 locations

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

Phase 3

Recruiting

Conditions: Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
Resectable Pancreatic Adenocarcinoma

Interventions: Drug: Leucovorin Calcium
Drug: Fluorouracil
Drug: Irinotecan Hydrochloride
Drug: Oxaliplatin
Procedure: Resection

First Posted Date: 2021-06-16

Last Posted Date: 2024-08-28

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 378

Registration Number: NCT04927780

Locations: 🇳🇱
Amphia Hospital, Breda, Netherlands
🇳🇱
Medisch Spectrum Twente, Enschede, Netherlands
🇳🇱
Tjongerschans Hospital, Heerenveen, Netherlands

and more 19 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy